# Aligos Therapeutics (ALGS) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ALGS
## Company Profile
- Ticker: ALGS
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Cardio-Metabolic
## Stock Data
- Close: 7 USD
- Market cap: 32488170.75 USD
- Last updated: 2026-08-12
## Business Overview
### Liver and Viral Diseases
Aligos Therapeutics develops small-molecule and oligonucleotide therapies for liver and viral diseases. Its lead clinical effort targets chronic hepatitis B through suppression of viral antigen production.
### Pevifoscorvir Sodium
Pevifoscorvir sodium is an antisense oligonucleotide designed to reduce hepatitis B surface antigen. The candidate is being evaluated in the Phase 2 B-SUPREME study across HBeAg-positive and HBeAg-negative patient cohorts.
### Combination-Oriented Development
Aligos is assessing whether deep antigen reduction can improve immune control and support finite treatment strategies, potentially in combination with other antiviral or immunomodulatory agents.
## Why The Stock Is Moving

The latest monitored company update is “Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China.” The corresponding closing-price reaction is not yet available.

## Future Catalysts

- Second interim analysis from the HBeAg-positive B-SUPREME cohort in the second half of 2026.
- Topline data from both HBeAg-positive and HBeAg-negative B-SUPREME cohorts in 2027.

## Recent News
- 2026-08-12 20:05 EST — [Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China](https://biopharmsignal.com/news/ALGS/aligos-therapeutics-announces-first-participant-dosed-in-the-phase-1-study-of-it-5a510178) — Source: Aligos Therapeutics
- 2026-08-06 12:00 EST — [Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/ALGS/aligos-therapeutics-reports-recent-business-progress-and-second-quarter-2026-fin-563b3b45) — Source: Aligos Therapeutics
- 2026-07-30 12:00 EST — [Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026](https://biopharmsignal.com/news/ALGS/aligos-therapeutics-to-announce-2nd-quarter-2026-financial-results-on-august-6-2-0808d448) — Source: Aligos Therapeutics
- 2026-07-13 12:00 EST — [Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection](https://biopharmsignal.com/news/ALGS/aligos-therapeutics-announces-the-completion-of-enrollment-in-the-phase-2-b-supr-4b435b0f) — Source: Aligos Therapeutics
- 2026-07-06 20:05 EST — [Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection](https://biopharmsignal.com/news/ALGS/aligos-therapeutics-receives-upfront-payment-of-25m-usd-from-the-exclusive-licen-d14ff076) — Source: Aligos Therapeutics